Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Chapter 166 [1] in the new Mandell textbook was written before the current Ebola outbreak, so I thought it would be interesting to read View Postit again and check whether the ‘old’ recommendations for personal protection were still valid now that we have learned much more during the ongoing outbreak. In Continue reading Preventing Ebola Transmission
We are told by Tom Frieden / CDC that it was a “protocol breach” when a nurse in Texas taking care of US Ebola patient no. 1 got infected? At the same news conference, he tells us he doesn’t know what kind of breach actually occurred. So what is he talking Continue reading Ebola and “Breach of Protocol”: Makes Me Bristle…
Despite all the concern about the emergence of CRE pathogens worldwide, it is quite difficult to obtain hard quantitative, prospectively collected incidence figures. A recent article by Robert [1] and colleagues provides useful data from France. Using a practical definition of carbapenem-non-susceptibility (ertapenem > 0.5, imipenem, meropenem > 2, doripenem > 1), Continue reading CRE Surveillance Data from France